Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls

46k
Total downloads
355k
Total views and downloads

Articles

EDITORIAL

Published on 18 Mar 2021

Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls

Amir Garakani
Rafael C. Freire
James W. Murrough

doi 10.3389/fpsyt.2021.662963

4,334 views

REVIEW

Published on 23 Dec 2020

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

Amir Garakani
James W. Murrough
Rafael C. Freire
Robyn P. Thom
Kaitlyn Larkin
Frank D. Buono
Dan V. Iosifescu

doi 10.3389/fpsyt.2020.595584

381,373 views
295 citations

REVIEW

Published on 19 Nov 2020

Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology

Madeeha Nasir
Daniel Trujillo
Jessica Levine
Jennifer B. Dwyer
Zachary W. Rupp
Michael H. Bloch

doi 10.3389/fpsyt.2020.548505

36,475 views
65 citations

REVIEW

Published on 15 May 2020

Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis

Gustavo E. Tafet
Charles B. Nemeroff

doi 10.3389/fpsyt.2020.00443

39,657 views
160 citations

STUDY PROTOCOL

Published on 13 Dec 2019

A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD

Marijn Lijffijt
Charles E. Green
Nicholas Balderston
Tabish Iqbal
Megan Atkinson
Brittany Vo-Le
Bylinda Vo-Le
Brittany O’Brien
Christian Grillon
1 more
Sanjay J. Mathew

doi 10.3389/fpsyt.2019.00846

21,856 views
17 citations

Share on

Frontiers in Psychiatry

Frontiers in Psychiatry

Psychopharmacology
Mood Disorders

Impact

355kTopic views
306kArticle views
46kArticle downloads